Stephen Davis - Jan 6, 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Jan 6, 2022
Transactions value $
-$85,700
Form type
4
Date filed
1/10/2022, 05:22 PM
Previous filing
Jan 6, 2022
Next filing
Feb 25, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +9.53K +18.01% 62.4K Jan 6, 2022 Direct F1, F2
transaction ACAD Common Stock Sale -$85.7K -3.72K -5.96% $23.05 58.7K Jan 6, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -9.53K -33.33% $0.00 19.1K Jan 6, 2022 Common Stock 9.53K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 1 share of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program.
F3 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F4 The restricted stock units vest in four equal annual installments beginning January 6, 2021.